Binds Cancer Cell Or Component Or Product Thereof (e.g., Cell-surface Antigen, Etc.) Patents (Class 530/389.7)
  • Patent number: 10344092
    Abstract: The present invention is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of CD32B and one binding site specific for an epitope of CD79b (i.e., a “CD32B×CD79b bi-specific monovalent Fc diabody”). The bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to CD32B and CD79b. The invention is directed to such compositions, to pharmaceutical compositions that contain such bi-specific monovalent Fc diabodies and to methods for their use in the treatment of inflammatory diseases or conditions, and in particular, systemic lupus erythematosus (SLE) and graft vs. host disease.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: July 9, 2019
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Kalpana Shah, Ezio Bonvini, Paul A. Moore, Wei Chen
  • Patent number: 9908938
    Abstract: The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 6, 2018
    Assignees: MacroGenics, Inc., Duke University
    Inventors: Scott Koenig, Leslie S. Johnson, Chia-Ying Kao Lam, Liqin Liu, Jeffrey Lee Nordstrom, Barton F. Haynes, Guido Ferrari
  • Patent number: 9907942
    Abstract: This invention provides methods and systems uniquely capable of enhancing medicant delivery and/or effectiveness through the use of energy to predictably disrupt membranes and mechanically and thermally modulate cells and tissues. In exemplary embodiments, the methods and systems disclosed herein are capable of modulating multiple layers of tissue. In an exemplary embodiment, the energy is acoustic energy (e.g., ultrasound). In other exemplary embodiments, the energy is photon based energy (e.g., IPL, LED, laser, white light, etc.), or other energy forms, such radio frequency electric currents, or various combinations of acoustic energy, electromagnetic energy and other energy forms or energy absorbers such as cooling. Medicants can be first introduced to the region of interest by diffusion, circulation, and/or injection. An exemplary system for enhancing medicant delivery and/or effectiveness comprises a control system, a probe, and a display or indicator system.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: March 6, 2018
    Assignee: GUIDED THERAPY SYSTEMS LLC
    Inventors: Michael H. Slayton, Peter G. Barthe
  • Publication number: 20150140018
    Abstract: An object is to find a target molecule effective for cancer treatments and the like and to provide an antibody capable of specifically binding to the molecule, an anticancer agent comprising the antibody as an active ingredient, and so forth. Hence, prostate cancer cell lines (LNCaP-CR cells and LNCaP cells) were compared by SST-REX, and CXADR was identified as a molecule involved in tumor formation and so on. Then, a monoclonal antibody against CXADR was prepared, and the anti-cancer activity, ADCC activity, CDC activity, and so forth were examined. The result revealed that an antibody capable of binding to an epitope present at positions 181 to 230 of a CXADR protein derived from human exhibited an anti-cancer activity against prostate cancer cells, pancreatic cancer cells, and colorectal cancer cells. Further, it was also revealed that the antibody had an ADCC activity and a CDC activity. Moreover, the structures of light chain and heavy chain variable regions of the antibody were successfully determined.
    Type: Application
    Filed: May 13, 2013
    Publication date: May 21, 2015
    Applicants: MEDICAL & BIOLOGICAL LABORATORIES CO., LTD., MICROBIAL CHEMISTRY RESEARCH FOUNDATION
    Inventors: Manabu Kawada, Hiroyuki Inoue, Shuichi Sakamoto, Masunori Kajikawa, Masahito Sugiura, Sakiko Urano
  • Patent number: 9028818
    Abstract: The invention relates to antibodies binding to the proteins forming adrenomedullin receptors, and to the uses thereof as a drug.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: May 12, 2015
    Assignees: Universite d'Aix-Marseille, Assitance Publique Hôpitaux de Marseille
    Inventors: L'Houcine Ouafik, Kamel Mabrouk, Itidal Kaafarany, Pierre-Marie Martin
  • Publication number: 20150125449
    Abstract: Provided herein are monovalent antibody constructs. In specific embodiments is a monovalent antibody construct comprising: an antigen-binding polypeptide construct which monovalently binds an antigen; and a dimeric Fc polypeptide construct comprising a CH3 domain, said construct comprising two monomeric Fc polypeptides, wherein one said monomeric Fc polypeptide is fused to at least one polypeptide from the antigen-binding polypeptide construct. These therapeutically novel molecules encompass monovalent constructs that display an increase in binding density and Bmax (maximum binding at a target to antibody ratio of 1:1) to a target cell displaying said antigen as compared to a corresponding monospecific bivalent antibody construct with two antigen binding regions. Provided herein are methods for creation of monovalent antibody constructs that shows superior effector efficacy as compared to the corresponding bivalent antibody construct at equimolar concentrations.
    Type: Application
    Filed: May 8, 2013
    Publication date: May 7, 2015
    Inventors: Gordon Yiu Kon Ng, Surjit Bhimarao Dixit, Thomas Spreter Von Kreudenstein
  • Publication number: 20150119557
    Abstract: We describe cell culture media for in vitro culture of a human cancer cell of the lymphocyte lineage (e.g., leukemia, lymphoma, or other blasts) or a precursor thereof, especially T-cell acute lymphoblastic leukemia lymphoma (T-ALL), as well as methods for at least maintenance, propagation, or both of the human cancer cell or its precursor.
    Type: Application
    Filed: April 12, 2013
    Publication date: April 30, 2015
    Applicants: THE UNIVERSITY OF MIAMI, THE BRITISH COLUMBIA CANCER AGENCY BRANCH, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Andrew P. Weng, Jon C. Aster, Tan A. Ince
  • Publication number: 20150118254
    Abstract: The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: October 30, 2014
    Publication date: April 30, 2015
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu
  • Publication number: 20150111279
    Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 23, 2015
    Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
  • Publication number: 20150104879
    Abstract: Provided is method of diagnosing liver cancer in a subject, the method comprising contacting a sample from a subject with a substance that specifically binds to transmembrane emp24 domain trafficking protein 2 (TMED2), cluster of differentiation 43 (CD43), or any combination thereof on the surface of a microvesicle; and measuring the level of the substance bound to microvesicles in the sample; and related methods and compositions.
    Type: Application
    Filed: July 2, 2014
    Publication date: April 16, 2015
    Inventors: Ye-ryoung YONG, Hyun-ju Kang, Ga-hee Kim, Kyung-hee Park, Jong-myeon Park
  • Publication number: 20150098900
    Abstract: The invention provides anti-FcRH5 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: June 24, 2014
    Publication date: April 9, 2015
    Inventors: Allen J. Ebens, Meredith C. Hazen, Jo-Anne Hongo, Jennifer W. Johnston, Teemu T. Junttila, Ji Li, Andrew G. Polson
  • Publication number: 20150093397
    Abstract: Methods to improve the success of cancer therapies that target CD37 are provided. Kits comprising reagent useful in the methods are further provided.
    Type: Application
    Filed: March 29, 2013
    Publication date: April 2, 2015
    Inventor: Christina N. Carrigan
  • Publication number: 20150079106
    Abstract: The invention relates to methods for the prophylaxis and treatment of breast cancer using one or more antagonists of artemin function, such as anti-artemin polynucleotides or anti-artemin antibodies and antibody fragments, and uses of these antagonists. In particular, the invention relates to the resensitisation of therapy-resistance breast cancer cells to anti-cancer therapies by antagonism of artemin functionality.
    Type: Application
    Filed: September 10, 2014
    Publication date: March 19, 2015
    Applicant: Auckland Uniservices Limited
    Inventor: Peter Edward LOBIE
  • Publication number: 20150064204
    Abstract: Antigen binding proteins that activate GITR are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided. The antigen binding proteins have value in therapeutic methods in which it is useful to to stimulate GITR signaling, thereby inducing or enhancing an immune response in a subject. Accordingly, the antigen binding proteins have utility in a varienty of immunotherapy treatments, including treatment of various cancers and infections.
    Type: Application
    Filed: August 28, 2014
    Publication date: March 5, 2015
    Inventors: Courtney BEERS, Jason C. O'NEILL, Ian FOLTZ, Randal R. KETCHEM, Julia C. PIASECKI
  • Publication number: 20150044233
    Abstract: Methods for determining the presence of cancer stem cells by detecting GD2 expression. Also provided are methods for reducing proliferation of cancer stem cells by contacting the cells with a GD2 targeting agent, such as an anti-GD2 antibody or a GD3 synthase inhibitor. GD3 synthase inhibitor compounds are also provided.
    Type: Application
    Filed: February 27, 2013
    Publication date: February 12, 2015
    Inventors: Venkata Battula, Michael Andreeff, Sendurai A. Mani, Tapasree Roy Sarkar
  • Patent number: 8952134
    Abstract: The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and C?3 and C?4 regions of a C? constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a C? constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: February 10, 2015
    Assignee: JN Biosciences LLC
    Inventors: J. Yun Tso, Naoya Tsurushita
  • Publication number: 20150037356
    Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.
    Type: Application
    Filed: September 6, 2012
    Publication date: February 5, 2015
    Applicants: CAMBRIDGE ENTERPRISE LIMITED, MEDIMMUNE LIMITED
    Inventors: John Elvin, Catherine Huntington, John Trowsdale, Alexander Barrow, Huan Cao
  • Publication number: 20150037355
    Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
    Type: Application
    Filed: January 4, 2012
    Publication date: February 5, 2015
    Applicants: SILLAJEN, INC., JENNEREX INC.
    Inventors: David Kirn, John Bell, Caroline Breitback, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim
  • Patent number: 8937165
    Abstract: The present invention relates to proteomic markers for early detection of hepatocellular carcinoma, compositions for detecting changes of these proteomic markers, kits for detection of hepatocellular carcinoma, methods for detecting proteomic markers including these compositions, methods for screening drugs for hepatocellular carcinoma using these proteomic markers, and antibodies specific for these proteomic markers.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: January 20, 2015
    Assignees: CBSBioscience Co., Ltd.
    Inventors: Jin Young Park, Seok Joo Hong, Jongmin Kim, Youngtack Shim
  • Publication number: 20150017637
    Abstract: The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to gene fusions as diagnostic markers and clinical targets for cancer.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 15, 2015
    Inventors: Arul Chinnaiyan, Yi-Mi Wu, Dan Robinson
  • Patent number: 8932593
    Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: January 13, 2015
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
  • Publication number: 20150004183
    Abstract: The present invention provides an antitumor agent having high safety, which is a molecular target drug against malignant tumors. An anti-malignant tumor agent characterized by containing, as an active ingredient, a substance targeting ribosomal proteins shows increased expression in malignant tumor cells. The substance of the present inventions targeting the ribosomal protein showing increased expression in the malignant tumor cell may be a substance involved in one of biological defense mechanisms which are considered to be intrinsically provided in a living body and prevent onset of disease even if cancer cells develop. Specifically, the ribosomal protein showing increased expression is RPL29 and/or RPS4X.
    Type: Application
    Filed: January 23, 2013
    Publication date: January 1, 2015
    Inventors: Yasuhiro Miyake, Kazuhide Yamamoto
  • Publication number: 20140377284
    Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Application
    Filed: March 20, 2014
    Publication date: December 25, 2014
    Applicants: JANSSEN PHARMACEUTICALS, INC., BIOCEROX PRODUCTS B.V.
    Inventors: Petrus Johannes SIMONS, Louis BOON, Jinquan LUO, Randall BREZSKI, Monica GOLDBERG
  • Publication number: 20140377779
    Abstract: A composition for breast cancer diagnosis using a material specifically binding to a polymeric immunoglobulin receptor (PIGR) or a fragment thereof, and a method for detecting breast cancer or acquiring information for breast cancer diagnosis using the composition.
    Type: Application
    Filed: March 17, 2014
    Publication date: December 25, 2014
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: YE-RYOUNG YONG, GA-HEE KIM, HYUN-JU KANG
  • Publication number: 20140370001
    Abstract: The present invention provides novel IgE antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor.
    Type: Application
    Filed: July 11, 2013
    Publication date: December 18, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Joseph A. Mollick, Pearline Teo, Paul J. Utz
  • Publication number: 20140364592
    Abstract: The invention relates to a cytotoxic modular antibody with a molecular weight of up to 6OkD, specifically binding to a cell surface target with a binding affinity of Kd<10?8 M, a method of producing such antibody and its use as a therapeutic.
    Type: Application
    Filed: August 27, 2014
    Publication date: December 11, 2014
    Inventors: Gottfried Himmler, Geert Mudde, Anton Bauer, Gerda Redl, Maximillian Woisetschlager
  • Publication number: 20140364481
    Abstract: Provided herein are kits, compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent RNA fusions as diagnostic markers and clinical targets for leukemia.
    Type: Application
    Filed: May 6, 2014
    Publication date: December 11, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Kojo Elenitoba-Johnson, Thirunavukkarasu Velusamy, Nallasivam Palanisamy, Anagh Sahasrabuddhe, Megan Lim, Arul Chinnaiyan
  • Publication number: 20140363429
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Application
    Filed: November 20, 2012
    Publication date: December 11, 2014
    Applicant: MedImmune LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
  • Publication number: 20140363448
    Abstract: The present invention relates to a method for treating breast cancer in a subject having a hyperactivation of the Epidermal Growth Factor Receptor 1 and/or 2 (EGFR and/or ErbB2 HER2), as compared to the normal subject population, or expressing deltaHER2, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the CUB domain-containing protein 1 (CDCP1).
    Type: Application
    Filed: December 21, 2012
    Publication date: December 11, 2014
    Inventors: Mohamed Bentires-Alj, Johannes Voshol, Abdullah Alajati, Deborah Bonenfant
  • Publication number: 20140356364
    Abstract: The present invention relates to antibodies (including anti-B7-H4 antibodies) and their antigen-binding fragments and to other molecules (including fusion proteins that bind to the cognate antigen/receptor, etc.) that are capable of immunospecifically binding to B7-H4 and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases. The invention particularly concerns the use of such molecules to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM—mediated immune suppression.
    Type: Application
    Filed: August 15, 2012
    Publication date: December 4, 2014
    Applicant: AMPLIMMUNE, INC.
    Inventors: Solomon Langermann, Linda Liu, Shannon Marshall
  • Publication number: 20140341809
    Abstract: High-affinity variants of the DMF5 TCR, and methods of use thereof for the treatment and imaging of cancer in a patient.
    Type: Application
    Filed: May 16, 2014
    Publication date: November 20, 2014
    Applicants: University of Massachusetts, University of Notre Dame
    Inventors: Brian G. Pierce, Zhiping Weng, Brian M. Baker
  • Publication number: 20140336363
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: December 12, 2012
    Publication date: November 13, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Carola Ries, Stefan Seeber, Marlene Thomas
  • Patent number: 8883980
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: November 11, 2014
    Assignee: Roche Glycart AG
    Inventors: Pablo Umaña, Peter Brünker, Claudia Ferrera Koller, Tobias Suter, Ursula Püntener, Ekkehard Mössner
  • Publication number: 20140328858
    Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3? terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.
    Type: Application
    Filed: May 2, 2014
    Publication date: November 6, 2014
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Richard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
  • Publication number: 20140322246
    Abstract: In one aspect, there is provided an antibody or a functional fragment thereof, wherein the antibody or functional fragment thereof is capable of binding specifically to high molecular weight melanoma associated antigen (HMW-MAA), and binding to an Fc? receptor.
    Type: Application
    Filed: October 4, 2011
    Publication date: October 30, 2014
    Applicant: KING'S COLLEGE LONDON
    Inventors: Sophia Karagiannis, Andrew Beavil, Frank Nestle
  • Publication number: 20140322244
    Abstract: The technology described herein relates to antibodies and/or polypeptides which bind to MIC and inhibit MIC shedding. Methods of using such antibodies and/or polypeptides for the treatment of cancer are also described herein.
    Type: Application
    Filed: May 1, 2014
    Publication date: October 30, 2014
    Applicant: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventor: Jennifer D. Wu
  • Publication number: 20140314793
    Abstract: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce cell death of the target cell. There is also provided methods of and pharmaceutical compositions for cell death induction and uses thereof.
    Type: Application
    Filed: April 11, 2014
    Publication date: October 23, 2014
    Applicant: BIOINVENT INTERNATIONAL AB
    Inventors: Björn Frendéus, Roland Carlsson, Ingrid Teige, Linda Mårtensson
  • Publication number: 20140315743
    Abstract: The invention relates to methods, compositions and kits for the diagnosis, detection, and treatment of ovarian cancer.
    Type: Application
    Filed: October 3, 2012
    Publication date: October 23, 2014
    Inventors: Karen Chapman, Joseph Wagner, Michael West, Jennifer Lorrie Kidd
  • Publication number: 20140314675
    Abstract: An objective of the present invention is to provide: a cancer stem cell isolated using a cell marker; a substantively homogeneous cancer stem cell population including said cancer stem cell; and a method of preparing said cancer stem cell population. Another objective of the present invention is to provide: a method for separating cancer stem cells with a high proliferative potential and those with a low proliferative potential; a method for inducing cancer stem cells to have a different proliferative potential; and cancer stem cells separated or induced by these separation or induction methods. A further objective of the present invention is to provide: a method of screening for pharmaceuticals using said cancer stem cell or cancer stem cell population; a method for detecting the presence of said cancer stem cell or cancer stem cell population and for identifying or quantifying the same.
    Type: Application
    Filed: September 7, 2012
    Publication date: October 23, 2014
    Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Atsuhiko Kato, Masami Suzuki
  • Publication number: 20140308278
    Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.
    Type: Application
    Filed: May 28, 2014
    Publication date: October 16, 2014
    Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
  • Publication number: 20140308301
    Abstract: Compositions including an antibody specific for CD44 are provided. These antibodies specifically bind to hematologic malignant cells. Methods to use the CD44 antibodies to target cells expressing CD44 for therapeutic and diagnostic purposes are also provided.
    Type: Application
    Filed: October 26, 2012
    Publication date: October 16, 2014
    Inventors: Thomas J. Kipps, Suping Zhang, Christina C. Wu
  • Publication number: 20140302020
    Abstract: Novel antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma. The invention also relates to cells expressing the humanized or hybrid antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.
    Type: Application
    Filed: June 23, 2014
    Publication date: October 9, 2014
    Inventors: Gilles Bernard TREMBLAY, Mario FILION, Traian SULEA
  • Publication number: 20140286859
    Abstract: The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compositions and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.
    Type: Application
    Filed: September 10, 2012
    Publication date: September 25, 2014
    Applicants: PSMA Development Company, LLC, Amgen Fremont Inc.
    Inventors: Paul J. Maddon, Gerald P. Donovan, William C. Olson, Norbert Schuelke, Jason Gardner, Dangshe Ma, Jaspal S. Kang, Larry Green
  • Publication number: 20140286861
    Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.
    Type: Application
    Filed: April 23, 2014
    Publication date: September 25, 2014
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Serengulam V. Govindan, Zhengxing Qu, Hans J. Hansen, David M. Goldenberg
  • Publication number: 20140271667
    Abstract: A method for inhibiting tumor cell migration or metastasis of a cancer in a mammalian subject comprises one or more of the steps of administering to a subject a therapeutically effective amount of a composition comprising a molecule that: suppresses focal adhesion kinase (FAK) activity or phosphorylation; suppresses ULK1 kinase activity; suppresses activation or signaling of the mTORC1 (Ser757) pathway; activates AMPK; activates FIP200; or activates LKB1, in a cancer cell. Still another method of inhibiting tumor cell migration involves inhibiting phosphorylation of ULK1 on Ser757 in subjects with lung cancer. Suppressing activation or signaling of the mTORC1 (Ser757) pathway in subjects is in one aspect useful in treating lung cancer.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: The Wistar Institute of Anatomy and Biology
    Inventors: Dario C. Altieri, Young Chan Chae
  • Publication number: 20140271685
    Abstract: In various embodiments various cancer specific antibodies and immunoconjugates are provided. In certain embodiments the antibodies specifically bind and are internalized into a prostate cancer cell, where the antibodies specifically binds cells that express or overexpress a CD46, and where the antibodies specifically bind sushi domain 1 of said CD46 (CD46 CPP1).
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Inventor: BIN LIU
  • Publication number: 20140255976
    Abstract: This invention relates to a surface coating for capture circulating rare cells, comprising a nonfouling composition to prevent the binding of non-specific cells and adsorption of serum components; a bioactive composition for binding the biological substance, such as circulating tumor cells; with or without a linker composition that binds the nonfouling and bioactive compositions. The invention also provide a surface coating for capture and purification of a biological substance, comprising a releasable composition to release the non-specific cells and other serum components; a bioactive composition for binding the biological substance, such as circulating tumor cells; with or without a linker composition that binds the releasable and bioactive compositions. The present invention also discloses a novel microfluidic chip, with specific patterned microstructures to create a flow disturbance and increase the capture rate of the biological substance.
    Type: Application
    Filed: June 28, 2012
    Publication date: September 11, 2014
    Inventors: Ying-Chih Chang, Han-Chung Wu, Po-Yuan Tseng
  • Patent number: 8829164
    Abstract: Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: September 9, 2014
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Kerry Whalen, Steve Bottega, Andrea Boudrow, Lyne Breault, Ting Chen, James Gifford, May Han, Jinwei Jiang, Lorena Lerner, Qing Liu, Kristan Meetze, Sylvie Vincent, Solly Weiler, William M. Winston, Jr., Jeno Gyuris
  • Publication number: 20140248294
    Abstract: Provided are novel methods and compositions for the diagnosis, prognosis and treatment of gynecological tumors, in particular uterine leiomyoma (UL). Furthermore, novel methods and compositions for the treatment of diseases characterized by an aberrant growth of mesenchymal stem cells and their descendants and for the treatment of pituitary and prostate tumors are described.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 4, 2014
    Applicant: UNIVERSITY OF BREMEN
    Inventors: Jörn Bullerdiek, Dominique N. Markowski
  • Publication number: 20140242095
    Abstract: The invention relates to modulating the SIRP?—CD47 interaction in order to treat hematological cancer and compounds therefor. In particular, there is also provided SIRP? antibodies and antibody fragments, preferably used for treating hematological cancer.
    Type: Application
    Filed: October 19, 2012
    Publication date: August 28, 2014
    Applicant: University Health Network
    Inventors: Jean C. Y. Wang, Jayne S. Danska, John Dick, Sachdev Sidhu, Maruti Uppalapati